MedPath

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3

Phase 3
Completed
Conditions
Dry Eye Syndromes
Dry Eye
Interventions
Drug: Placebo
Registration Number
NCT03937882
Lead Sponsor
ReGenTree, LLC
Brief Summary

The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
700
Inclusion Criteria
  • Be at least 18 years of age;
  • Provide written informed consent;
  • Have a subject reported history of dry eye for at least 6 months;
  • Have a history of use or desire to use eye drops for dry eye symptoms within 6 months
Exclusion Criteria
  • Have any clinically significant slit-lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
  • Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
  • Have an uncontrolled systemic disease;
  • Be a woman who is pregnant, nursing or planning a pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboIt is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
RGN-259RGN-259RGN-259: It is a preservative-free, sterile eye drop solution containing Thymosin beta 4
Primary Outcome Measures
NameTimeMethod
Ocular Discomfort 6-point (0=none, 5=worst) scale15 days after first dosing

Mean change from baseline to Day 15 of Ocular Discomfort severity

Corneal staining15 days after first dosing

Mean change from baseline to Day 15 of Inferior Corneal Fluorescein Staining

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (18)

Cornea and Cataract Consultants of Arizona

🇺🇸

Phoenix, Arizona, United States

Eye Research Foundation

🇺🇸

Newport Beach, California, United States

Vision Institute

🇺🇸

Colorado Springs, Colorado, United States

Dovilan Wyatt MD, LLC

🇺🇸

Chicago, Illinois, United States

Whitson Vision

🇺🇸

Indianapolis, Indiana, United States

Midwest Cornea Associates, LLC

🇺🇸

Indianapolis, Indiana, United States

The Eye Care Institute

🇺🇸

Louisville, Kentucky, United States

Andover Eye Associates

🇺🇸

Warwick, Rhode Island, United States

Center For Sight

🇺🇸

Henderson, Nevada, United States

Oculus Research, Inc. at the Eye Care Center

🇺🇸

Raleigh, North Carolina, United States

Scroll for more (8 remaining)
Cornea and Cataract Consultants of Arizona
🇺🇸Phoenix, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.